Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.45 |
| ▸ | FPR2 | P25090 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12965349 | 0.84 | DRD2 (0.45) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL12082229 | 0.82 | FFAR1 (0.56) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL12082307 | 0.82 | FFAR1 (0.56) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL2448887 | 0.81 | FPR1 (0.47) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL2447116 | 0.81 | FPR1 (0.47) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL12004750 | 0.81 | FPR1 (0.47) | FPR1FPR2FFAR1SYKROCK2 | |
| SCHEMBL30097125 | 0.80 | FFAR1 (0.49) | FPR1FPR2FFAR1PPARGDRD2 | |
| SCHEMBL791983 | 0.80 | FFAR1 (0.49) | FPR1FPR2FFAR1PPARGDRD2 | |
| SCHEMBL12006634 | 0.78 | MAPT (0.46) | FPR1FPR2FFAR1SYKPPARG | |
| SCHEMBL791700 | 0.78 | MAPT (0.46) | FPR1FPR2FFAR1SYKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | FPR1 3993/4885FPR2 4446/4885FFAR1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.